Fissure Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

An anal fissure is a tear or ulcer in the anoderm — the specialised squamous epithelium lining the lower anal canal — typically occurring at the posterior midline (90% of cases) or less commonly the anterior midline. Acute fissures (under 6 weeks' duration) have a characteristic linear tear appearance and often heal with conservative management. Chronic fissures (over 6 weeks) develop a triad of features: a sentinel skin tag at the external margin, exposure of the internal sphincter fibres at the base of the ulcer, and a hypertrophied anal papilla at the dentate line. The pathophysiology of chronic fissures centres on elevated internal anal sphincter (IAS) tone: high resting anal pressure reduces blood flow to the posterior commissure, impairing healing of what may begin as a minor traumatic tear.

The condition causes severe sharp pain during and after defaecation (often described as 'passing broken glass'), bright red rectal bleeding on wiping, and intense sphincter spasm. The fear of pain leads to constipation and faecal avoidance, which paradoxically perpetuates the problem through harder, larger stools that re-traumatise the fissure. The cycle of pain, spasm, ischaemia, and failed healing defines chronic fissure pathophysiology.

Diagnosis is clinical — inspection of the perineum and gentle spreading of the buttocks is usually sufficient; proctoscopy and digital rectal examination are deferred until after treatment in acute painful cases. Treatment aims to break the cycle by reducing IAS tone, improving anodermal blood supply, and allowing healing. Options progress from conservative measures through topical chemical sphincterotomy to botulinum toxin injection and definitive surgical lateral internal sphincterotomy.

Anal fissure treatment addresses both acute fissures (recent onset, often from constipation, hard stool passage, or childbirth) and chronic fissures (non-healing ulcers with raised sphincter tone). Primary chronic anal fissure — occurring in the absence of specific underlying disease — is the most common form and responds best to treatment. Secondary fissures occurring in the context of Crohn's disease, HIV, syphilis, herpes simplex, tuberculosis, or malignancy require treatment of the underlying condition and specialist management, as standard fissure surgery may impair wound healing and continence in these cases.

Fissures in atypical locations (lateral, multiple fissures, or those in patients with diarrhoeal disease rather than constipation) should prompt investigation for inflammatory bowel disease, sexually transmitted infections, or malignancy before committing to fissure-specific treatment. Approximately 8–10% of apparently idiopathic anal fissures in tertiary referral series have an underlying causative condition identified on investigation.

All patients with symptomatic anal fissures are candidates for treatment; the specific modality depends on fissure duration, severity, and prior treatment history. Initial conservative management is appropriate for all acute fissures and as first-line therapy for chronic fissures. Patients who fail conservative management after 4–8 weeks are candidates for topical nitrate or calcium channel blocker therapy. Those who fail two courses of topical therapy are candidates for botulinum toxin injection. Surgical lateral internal sphincterotomy is indicated for chronic fissures that have failed non-surgical treatment, or for patients in whom rapid resolution is required.

Contraindications to lateral internal sphincterotomy include pre-existing faecal incontinence or borderline continence — particularly women with prior obstetric sphincter injuries — where further sphincter division risks incontinence. Low resting anal pressures on anorectal physiology testing are a relative contraindication. Botulinum toxin injection is preferred in patients with continence concerns. Crohn's disease fissures are a relative contraindication to sphincterotomy due to poor wound healing and high fistula formation risk.

Conservative management includes dietary fibre supplementation (20–30 g/day), adequate fluid intake, stool softeners (docusate sodium, lactulose), warm sitz baths for 10–15 minutes after defaecation to relax the sphincter and improve perineal blood flow, and avoidance of straining. Acute fissures heal with conservative management alone in 50–60% of cases within 4–6 weeks. Topical 0.2–0.4% glyceryl trinitrate (GTN) ointment applied twice daily to the anal margin is the most widely used pharmacological agent; it reduces IAS pressure by 30–40% and achieves healing in 50–65% of chronic fissures. Headache (due to systemic nitrate absorption) limits tolerability in up to 30% of patients. Diltiazem 2% cream (calcium channel blocker) achieves comparable healing rates (65–75%) with significantly fewer headaches and is the preferred topical agent in many centres.

Botulinum toxin (Botox) injection into the internal anal sphincter reduces resting anal pressure by 30–40% for 3–4 months, achieving healing in 60–80% of chronic fissures with a single treatment. The injection is performed in the outpatient or day procedure setting; recurrence rates of 30–40% at 3 years have been reported. Surgical lateral internal sphincterotomy (LIS) divides a portion of the distal IAS — either under direct vision (open technique) or via a subcutaneous incision (closed technique) — permanently reducing resting anal tone. LIS achieves healing in 95–98% of cases and is the most effective treatment for chronic anal fissure. The procedure is performed as a day case under general or local anaesthesia and takes approximately 20–30 minutes.

Lateral internal sphincterotomy provides the highest cure rates of any fissure treatment — healing in over 95% of cases with pain relief beginning within days of the procedure. Published data from randomised controlled trials and systematic reviews consistently demonstrate its superiority over topical agents and botulinum toxin for complete fissure healing and freedom from recurrence. Most patients experience complete resolution of anal pain, cessation of bleeding, and return to normal bowel function within 2–4 weeks post-operatively.

Topical treatments offer the advantage of non-invasiveness and are associated with no incontinence risk; their clinical benefit in appropriately selected acute and early chronic fissures is well documented. Botulinum toxin injection achieves a satisfactory cure rate with minimal risk and is increasingly preferred as an intermediate step before sphincterotomy in patients concerned about incontinence risk. Conservative measures alone are appropriate for acute fissures and produce cure in a majority of cases when combined with optimal stool management, avoidance of constipation, and warm sitz bath analgesia.

The most clinically important risk of lateral internal sphincterotomy is faecal incontinence — difficulty controlling flatus or liquid stool. Reported rates of minor incontinence (intermittent gas or liquid soiling) are 5–10%; minor but persistent flatus incontinence is reported in up to 30% in some long-term series, though often clinically insignificant. Rates of faecal urgency (urgency incontinence for solid stool) are lower, approximately 1–3%. These risks are substantially higher in women with prior obstetric sphincter injuries and in elderly patients. Meticulous surgical technique limiting sphincter division to the minimum needed is essential. Other surgical complications include wound infection (2–5%), haematoma (1–2%), and delayed healing (rare).

Topical GTN causes clinically significant headache in up to 30% of patients, limiting compliance and efficacy. Topical diltiazem has a much lower headache rate (under 5%) and good tolerability. Botulinum toxin injection is associated with minor temporary incontinence in 5–10% of patients (flatus or liquid soiling) that resolves within the 3–4 month duration of drug action. Injection site reactions are uncommon. Post-operative pain after LIS is generally mild and controlled with simple analgesia; severe or escalating post-operative pain should be assessed for haematoma or infection.

After conservative or topical treatment, patients are reviewed at 6–8 weeks to assess healing progress. Those with incomplete healing at this interval should be referred for consideration of botulinum injection or surgical sphincterotomy. Following LIS, a post-operative review at 4–6 weeks confirms healing and assesses continence. Patients are advised to maintain high-fibre diet and adequate fluid intake permanently to prevent recurrence, as constipation can cause new fissures even in surgically healed cases. Warm sitz baths continue for 1–2 weeks post-operatively for comfort.

Most patients resume normal daily activities within 1–2 weeks of LIS. Strenuous physical activity and sexual intercourse are restricted for 2–4 weeks. Driving is generally safe within 48–72 hours of the procedure when adequate pain control is achieved. Patients should be counselled that incomplete healing or recurrence after conservative treatment is common but does not indicate treatment failure — progressive treatment escalation is the norm. Long-term outcome data show less than 5% recurrence after successful LIS, making it one of the most durable treatments in colorectal surgery.

Conservative management and topical treatment costs are minimal — sitz bath equipment costs under USD 20 and topical GTN or diltiazem costs USD 10–40 per month in most markets. Botulinum toxin injection in a day procedure setting costs USD 500–1,500 in the US including the drug and facility fee. Lateral internal sphincterotomy costs USD 3,000–8,000 in the US including anaesthesia and facility fees; UK private costs are GBP 1,500–3,500, with NHS funding available for clinically indicated cases.

Medical tourism for anal fissure surgery is cost-effective in India, Thailand, and Turkey. Day case LIS at accredited facilities in India costs USD 400–1,200 — 70–85% less than US prices — with experienced colorectal surgeons performing high volumes of proctological procedures. The short hospital stay and rapid recovery make this an accessible medical tourism option. Patients should confirm the surgeon's experience specifically with LIS and post-operative follow-up arrangements before planning overseas surgery.

Anal advancement flap (anoplasty) is a surgical alternative to LIS for fissures in patients with borderline or low resting anal pressure, where further sphincter division would risk incontinence. The procedure recruits healthy skin into the fissure bed without dividing the sphincter and achieves healing in 70–85% of cases with no incontinence risk. It is technically more demanding than LIS and is performed in specialist colorectal units.

Cryotherapy and laser treatment for fissures have limited evidence and are not recommended by current ASCRS or ACPGBI guidelines as standard options. Nifedipine cream, minoxidil topical preparations, and oral diltiazem have been evaluated in small studies with modest results and are not in routine clinical use. Addressing constipation with long-term dietary changes, increased physical activity, and stool softeners remains the most important preventive measure against both primary fissure development and recurrence after treatment.